Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVICCI: Antiretroviral Intensification with Cenicriviroc for HIV-associated Cognitive Impairment
2015-002955-85Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cenicriviroc in human immunodeficiency virus infection (HIV) and HIV encephalopathy (HAND), sponsored by Imperial College London. Primary endpoints: Acceptability, safety and tolerability of cenicriviroc intensification, Cerebrospinal fluid exposure of cenicriviroc and 1 more. Started Dec 2015; status: terminated.
02
Drugs
cenicriviroc
03
Conditions
human immunodeficiency virus infection (HIV)HIV encephalopathy (HAND)
Beyond the preview
Go deeper on 2015-002955-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002955-85.